Noble Financial Issues Negative Forecast for Ocugen Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Noble Financial lowered their Q3 2026 earnings per share estimates for Ocugen in a research note issued on Wednesday, March 25th. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Noble Financial also issued estimates for Ocugen’s Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.26) EPS.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The firm had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.86 million.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Chardan Capital reiterated a “buy” rating and set a $7.00 target price on shares of Ocugen in a research note on Wednesday. Oppenheimer assumed coverage on shares of Ocugen in a report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 target price on the stock. HC Wainwright raised their price target on shares of Ocugen from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group started coverage on shares of Ocugen in a report on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Ocugen Price Performance

Shares of NASDAQ OCGN opened at $1.87 on Friday. Ocugen has a twelve month low of $0.57 and a twelve month high of $2.73. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04. The company has a market capitalization of $613.17 million, a price-to-earnings ratio of -8.13 and a beta of 2.75. The business has a 50 day simple moving average of $1.74 and a 200-day simple moving average of $1.54.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cora Capital Advisors LLC grew its stake in Ocugen by 27.5% during the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock worth $41,000 after buying an additional 6,500 shares during the last quarter. Jain Global LLC lifted its stake in Ocugen by 7.2% in the fourth quarter. Jain Global LLC now owns 114,690 shares of the company’s stock valued at $155,000 after buying an additional 7,686 shares during the last quarter. Lanham O Dell & Company Inc. boosted its holdings in shares of Ocugen by 7.7% during the third quarter. Lanham O Dell & Company Inc. now owns 140,000 shares of the company’s stock valued at $228,000 after acquiring an additional 10,000 shares during the period. Procyon Advisors LLC grew its position in shares of Ocugen by 5.5% during the third quarter. Procyon Advisors LLC now owns 211,100 shares of the company’s stock worth $344,000 after acquiring an additional 11,000 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after acquiring an additional 13,326 shares during the last quarter. Institutional investors and hedge funds own 10.27% of the company’s stock.

Key Stories Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised several 2026 quarterly EPS forecasts (Q1–Q4 moved toward ($0.05) from ($0.06)), boosted FY2026 and materially raised long‑range revenue/earnings assumptions (FY2028–FY2030), and reiterated a “Buy” rating with a $10 price target — a constructive analyst endorsement that supports longer‑term upside. HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price
• Positive Sentiment: Chardan Capital assigned a Buy rating on Ocugen, adding another buy‑side vote that may attract momentum buyers or traders looking for analyst‑driven catalysts. Ocugen (NASDAQ:OCGN) Earns Buy Rating from Chardan Capital
• Neutral Sentiment: Consensus for FY2026 EPS remains negative (around ($0.20) per share), so while some analysts are lifting estimates, the market still expects a loss this year — keeping Ocugen in speculative/biotech territory.
• Negative Sentiment: Noble Financial lowered near‑term EPS estimates (Q3 2026 to ($0.07) and Q4 2026 to ($0.08); FY2026 to ($0.26)), signaling concern about near‑term performance and adding selling pressure from cautious shops.
• Negative Sentiment: Clinical setback: Phase II data for OCU410 in an eye disease trial showed lower lesion reduction versus earlier results (despite a reported 31% improvement), which triggered the immediate stock weakness as investors reassess clinical and regulatory risk. Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.